Elutia
ELUTElutia Inc. is a biotechnology company specializing in the development of proprietary drug-eluting biomatrix products designed to improve the interaction between implanted medical devices and human tissue.
Table of contents
Earnings
Next report
Aug 14, 2026 (in a month)Competitors
By market cap
Profile
Elutia Inc. is a biotechnology company specializing in the development of proprietary drug-eluting biomatrix products designed to improve the interaction between implanted medical devices and human tissue. The company focuses on reducing surgical complications such as infection, fibrosis, and implant rejection through advanced biologic scaffolds and local drug delivery systems. Their core value proposition lies in humanizing medicine by providing regenerative solutions that enhance patient outcomes in reconstructive and soft tissue repair procedures.
Elutia is a pioneer in antibiotic-eluting biologic matrices, having successfully commercialized and divested the first antibiotic-eluting envelope for cardiac implants.
Questions, answered.
- What is Elutia's market cap?
- Elutia (ELUT) has a market capitalization of $43.0M and trades on NASDAQ.
- Who are Elutia's competitors?
- Elutia's key competitors include Organogenesis, Integra LifeSciences, Medtronic, and others. These companies compete in similar markets and product categories.
- Who does Elutia partner with?
- Elutia's notable partners include Boston Scientific Corporation, Cardiac Pacemakers Inc.
- Where is Elutia headquartered?
- Elutia is headquartered in United States of America and employs approximately 54 people. It has been publicly traded since 2020.